Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Prostate Cancer

  Free Subscription


Articles published in Int J Urol

Retrieve available abstracts of 122 articles:
HTML format



Single Articles


    September 2020
  1. SHIOTA M, Machidori A, Abe T, Monji K, et al
    Impact of antiandrogen withdrawal syndrome in castration-resistant prostate cancer patients treated with abiraterone or enzalutamide.
    Int J Urol. 2020 Sep 15. doi: 10.1111/iju.14366.
    PubMed     Abstract available


  2. SUGIMURA R, Kawahara T, Uemura H
    Re: Geriatric 8 screening of frailty in patients with prostate cancer.
    Int J Urol. 2020 Sep 13. doi: 10.1111/iju.14371.
    PubMed    


  3. SHIGETA K, Kikuchi E, Matsushima M, Ogihara K, et al
    Relationship between radiation doses and erectile function deterioration in patients with localized prostate cancer treated with permanent prostate brachytherapy.
    Int J Urol. 2020 Sep 6. doi: 10.1111/iju.14358.
    PubMed     Abstract available


    August 2020
  4. KANEKO M, Yip W, Abreu AL
    Editorial Comment from Dr Kaneko et al. to Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility.
    Int J Urol. 2020 Aug 29. doi: 10.1111/iju.14362.
    PubMed    


  5. SHOJI S
    Editorial Comment from Dr Shoji to Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility.
    Int J Urol. 2020 Aug 29. doi: 10.1111/iju.14353.
    PubMed    


  6. KAWAHARA T
    Editorial Comment to Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer.
    Int J Urol. 2020 Aug 8. doi: 10.1111/iju.14346.
    PubMed    


  7. AYDIN AM, Gage K, Dhillon J, Cheriyan SK, et al
    Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility.
    Int J Urol. 2020 Aug 6. doi: 10.1111/iju.14321.
    PubMed     Abstract available


    July 2020
  8. IPPOLITO D, Querques G, Pecorelli A, Perugini G, et al
    Diagnostic accuracy of multiparametric magnetic resonance imaging combined with clinical parameters in the detection of clinically significant prostate cancer: A novel diagnostic model.
    Int J Urol. 2020 Jul 25. doi: 10.1111/iju.14316.
    PubMed     Abstract available


  9. MARTELL K
    Editorial Comment to High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term androgen deprivation therapy for very high-risk prostate cancer.
    Int J Urol. 2020 Jul 22. doi: 10.1111/iju.14328.
    PubMed    


  10. VAN POPPEL H, Abrahamsson PA
    Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer.
    Int J Urol. 2020 Jul 13. doi: 10.1111/iju.14303.
    PubMed     Abstract available


  11. KASAHARA T, Ishizaki F, Kazama A, Yuki E, et al
    High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term androgen deprivation therapy for very high-risk prostate cancer.
    Int J Urol. 2020 Jul 7. doi: 10.1111/iju.14305.
    PubMed     Abstract available


  12. HAGHSHENO MA, Hammarsten J, Peeker R, Behre CJ, et al
    Men with type 2 diabetes mellitus have a lower detection rate of prostate cancer.
    Int J Urol. 2020 Jul 6. doi: 10.1111/iju.14304.
    PubMed    


    June 2020
  13. NAKAI Y, Tanaka N, Asakawa I, Anai S, et al
    Biochemical control of the combination of cyclooxygenase-2 inhibitor and (125) I-brachytherapy for prostate cancer: Post hoc analysis of an open-label controlled randomized trial.
    Int J Urol. 2020 Jun 26. doi: 10.1111/iju.14294.
    PubMed     Abstract available


  14. MOMOTA M, Hatakeyama S, Soma O, Tanaka T, et al
    Geriatric 8 screening of frailty in patients with prostate cancer.
    Int J Urol. 2020 Jun 4. doi: 10.1111/iju.14256.
    PubMed     Abstract available


    May 2020
  15. KATO M
    Editorial Comment to Association of tumor burden with the eligibility of upfront intensification therapy in metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
    Int J Urol. 2020 May 30. doi: 10.1111/iju.14278.
    PubMed    


  16. HATAKEYAMA S, Narita S, Takahashi M, Sakurai T, et al
    Association of tumor burden with the eligibility of upfront intensification therapy in metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
    Int J Urol. 2020 May 16. doi: 10.1111/iju.14258.
    PubMed     Abstract available


    April 2020
  17. YOSHIDA S, Takahara T, Arita Y, Toda K, et al
    Patterns of failure after progressive site-directed therapy in oligo-progressive castration-resistant prostate cancer.
    Int J Urol. 2020 Apr 14. doi: 10.1111/iju.14249.
    PubMed    


    March 2020
  18. KAWAHARA T, Miyoshi Y, Uemura H
    Re: Current treatment strategies for advanced prostate cancer.
    Int J Urol. 2020 Mar 31. doi: 10.1111/iju.14237.
    PubMed    


  19. KATO T, Sugimoto M
    Quality of life in active surveillance for early prostate cancer.
    Int J Urol. 2020 Mar 6. doi: 10.1111/iju.14202.
    PubMed     Abstract available


  20. GHAFFARI H
    Re: Placement of SpaceOAR hydrogel spacer for prostate cancer patients treated with iodine-125 low-dose-rate brachytherapy.
    Int J Urol. 2020 Mar 5. doi: 10.1111/iju.14209.
    PubMed    


  21. TAKAHASHI S
    Editorial Comment to Treatment-induced changes in levels of brain natriuretic peptide in prostate cancer patients receiving gonadotropin-releasing hormone antagonists or agonists.
    Int J Urol. 2020 Mar 3. doi: 10.1111/iju.14214.
    PubMed    


    February 2020
  22. KIJIMA T, Ito M, Ishioka J, Matsuoka Y, et al
    Treatment-induced changes in levels of brain natriuretic peptide in prostate cancer patients receiving gonadotropin-releasing hormone antagonists or agonists.
    Int J Urol. 2020 Feb 19. doi: 10.1111/iju.14201.
    PubMed    


  23. SHIOTA M, Onozawa M, Hinotsu S, Eto M, et al
    Family history in primary hormone therapy for prostate cancer: Analysis from a community-based multi-institutional Japan-wide database.
    Int J Urol. 2020 Feb 10. doi: 10.1111/iju.14184.
    PubMed     Abstract available


  24. KITAGAWA Y
    Editorial Comment to Family history in primary hormone therapy for prostate cancer: Analysis from a community-based multi-institutional Japan-wide database.
    Int J Urol. 2020 Feb 10. doi: 10.1111/iju.14198.
    PubMed    


    January 2020
  25. UKIMURA O
    Editorial Comment from Dr Ukimura to Magnetic resonance imaging/transrectal ultrasonography fusion targeted prostate biopsy finds more significant prostate cancer in biopsy-naive Japanese men compared with the standard biopsy.
    Int J Urol. 2020 Jan 8. doi: 10.1111/iju.14168.
    PubMed    


    December 2019
  26. TAKEDA T, Tin AL, Corradi RB, Alvim R, et al
    Extensive disease among potential candidates for hemi-ablative focal therapy for prostate cancer.
    Int J Urol. 2019 Dec 13. doi: 10.1111/iju.14161.
    PubMed     Abstract available


  27. SHIOTA M
    Editorial Comment from Dr Shiota to Magnetic resonance imaging/transrectal ultrasonography fusion targeted prostate biopsy finds more significant prostate cancer in biopsy-naive Japanese men compared with the standard biopsy.
    Int J Urol. 2019 Dec 2. doi: 10.1111/iju.14156.
    PubMed    


    November 2019
  28. TAY KJ
    Editorial Comment to Focal salvage low-dose-rate brachytherapy for recurrent prostate cancer based on magnetic resonance imaging/transrectal ultrasound fusion biopsy technique.
    Int J Urol. 2019 Nov 30. doi: 10.1111/iju.14159.
    PubMed    


  29. FUJII S, Hayashi T, Honda Y, Terada H, et al
    Magnetic resonance imaging/transrectal ultrasonography fusion targeted prostate biopsy finds more significant prostate cancer in biopsy-naive Japanese men compared with the standard biopsy.
    Int J Urol. 2019 Nov 16. doi: 10.1111/iju.14149.
    PubMed     Abstract available


  30. YAMADA Y, Okihara K, Masui K, Ueno A, et al
    Focal salvage low-dose-rate brachytherapy for recurrent prostate cancer based on magnetic resonance imaging/transrectal ultrasound fusion biopsy technique.
    Int J Urol. 2019 Nov 13. doi: 10.1111/iju.14151.
    PubMed     Abstract available


  31. TSUMURA H
    Editorial Comment to Placement of SpaceOAR hydrogel spacer for prostate cancer patients treated with iodine-125 low-dose-rate brachytherapy.
    Int J Urol. 2019 Nov 3. doi: 10.1111/iju.14148.
    PubMed    


    October 2019
  32. SHIOTA M
    Editorial Comment to Validation and development of the CHAARTED criteria in patients with hormone-naive metastatic prostate cancer: A multi-institutional retrospective study in Japan.
    Int J Urol. 2019 Oct 23. doi: 10.1111/iju.14143.
    PubMed    


  33. AKAKURA K
    Editorial Comment to Impact of alternative antiandrogen therapy for Japanese prostate cancer patients in the era of new hormonal therapy.
    Int J Urol. 2019 Oct 21. doi: 10.1111/iju.14141.
    PubMed    


  34. OKAMOTO T, Hatakeyama S, Narita S, Arai Y, et al
    Validation and development of the CHAARTED criteria in patients with hormone-naive metastatic prostate cancer: A multi-institutional retrospective study in Japan.
    Int J Urol. 2019 Oct 15. doi: 10.1111/iju.14136.
    PubMed    


  35. NAKATA W, Yamamichi G, Tsujimura G, Tsujimoto Y, et al
    Impact of alternative antiandrogen therapy for Japanese prostate cancer patients in the era of new hormonal therapy.
    Int J Urol. 2019 Oct 11. doi: 10.1111/iju.14135.
    PubMed    


  36. MORITA M, Fukagai T, Hirayama K, Yamatoya J, et al
    Placement of SpaceOAR hydrogel spacer for prostate cancer patients treated with iodine-125 low-dose-rate brachytherapy.
    Int J Urol. 2019 Oct 6. doi: 10.1111/iju.14123.
    PubMed     Abstract available


    September 2019
  37. TANAKA N, Asakawa I, Hasegawa M, Fujimoto K, et al
    Low-dose-rate brachytherapy for prostate cancer: A 15-year experience in Japan.
    Int J Urol. 2019 Sep 24. doi: 10.1111/iju.14098.
    PubMed     Abstract available


  38. NINOMIYA S, Kawahara T, Tatenuma T, Miyoshi Y, et al
    Preference for enzalutamide capsules versus tablet pills in patients with prostate cancer.
    Int J Urol. 2019 Sep 18. doi: 10.1111/iju.14101.
    PubMed    


  39. KAWAMURA H, Kubo N, Sato H, Miyasaka Y, et al
    Quality of life in prostate cancer patients receiving particle radiotherapy: A review of the literature.
    Int J Urol. 2019 Sep 11. doi: 10.1111/iju.14102.
    PubMed     Abstract available


    August 2019
  40. MURAKAMI Y, Satoh T, Tsumura H, Tabata KI, et al
    Quality of life outcomes after low dose-rate brachytherapy for localized prostate cancer: Current status and future perspectives.
    Int J Urol. 2019 Aug 22. doi: 10.1111/iju.14090.
    PubMed     Abstract available


    July 2019
  41. KIMURA T, Koike Y, Aikawa K, Kimura S, et al
    Short-term impact of androgen deprivation therapy on bone strength in castration-sensitive prostate cancer.
    Int J Urol. 2019 Jul 28. doi: 10.1111/iju.14077.
    PubMed     Abstract available


  42. SHIGEMURA K, Fujisawa M
    Editorial Comment to Quality of life after external beam radiotherapy for localized prostate cancer: Comparison with other modalities.
    Int J Urol. 2019 Jul 25. doi: 10.1111/iju.14085.
    PubMed    


  43. FUKUHARA S
    Editorial Comment to Erectile function recovery at 12 months after radical prostatectomy for prostate cancer is not associated with overall survival.
    Int J Urol. 2019 Jul 8. doi: 10.1111/iju.14064.
    PubMed    


  44. ISHIKAWA H, Tsuji H, Murayama S, Sugimoto M, et al
    Particle therapy for prostate cancer: The past, present and future.
    Int J Urol. 2019 Jul 8. doi: 10.1111/iju.14041.
    PubMed     Abstract available


    June 2019
  45. SEKIGUCHI A, Tsumura H, Kawakami S, Satoh T, et al
    Relationship between the dose to the bulbomembranous urethra and stricture after high dose-rate brachytherapy for prostate cancer: Matched-pair analysis.
    Int J Urol. 2019 Jun 30. doi: 10.1111/iju.14045.
    PubMed    


  46. TAKEDA T, Benfante NE, Assel M, Mulhall JP, et al
    Erectile function recovery at 12 months after radical prostatectomy for prostate cancer is not associated with overall survival.
    Int J Urol. 2019 Jun 25. doi: 10.1111/iju.14043.
    PubMed    


  47. ITO K, Oki R, Sekine Y, Arai S, et al
    Screening for prostate cancer: History, evidence, controversies and future perspectives toward individualized screening.
    Int J Urol. 2019 Jun 10. doi: 10.1111/iju.14039.
    PubMed     Abstract available


  48. HONGO F, Okihara K, Kitamura K, Fujihara A, et al
    Prostate cancer meeting the Japanese active surveillance criteria and diagnosed by community-based prostate-specific antigen screening: A 21-year follow-up study.
    Int J Urol. 2019 Jun 10. doi: 10.1111/iju.14037.
    PubMed     Abstract available


    May 2019
  49. NAKAMURA K, Konishi K, Komatsu T, Ishiba R, et al
    Quality of life after external beam radiotherapy for localized prostate cancer: Comparison with other modalities.
    Int J Urol. 2019 May 26. doi: 10.1111/iju.14026.
    PubMed     Abstract available


  50. HATANO K, Tohyama N, Kodama T, Okabe N, et al
    Current status of intensity-modulated radiation therapy for prostate cancer: History, clinical results and future directions.
    Int J Urol. 2019 May 21. doi: 10.1111/iju.14011.
    PubMed     Abstract available


  51. AFFERI L, Baumeister P, Mordasini L, Mattei A, et al
    Editorial Comment to How does (68) Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?
    Int J Urol. 2019 May 13. doi: 10.1111/iju.14025.
    PubMed    


  52. BIANCHI L, Schiavina R, Borghesi M, Ceci F, et al
    How does (68) Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?
    Int J Urol. 2019 May 13. doi: 10.1111/iju.14012.
    PubMed     Abstract available


  53. YUASA T
    Editorial Comment to Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes.
    Int J Urol. 2019 May 12. doi: 10.1111/iju.14018.
    PubMed    


  54. TANAKA N, Nishimura K, Okajima E, Ina K, et al
    Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes.
    Int J Urol. 2019 May 5. doi: 10.1111/iju.14009.
    PubMed     Abstract available


    March 2019
  55. KOBAYASHI T
    Editorial Comment to Micro-ribonucleic acid expression signature of metastatic castration-resistant prostate cancer: regulation of NCAPH by antitumor miR-199a/b-3p.
    Int J Urol. 2019 Mar 4. doi: 10.1111/iju.13919.
    PubMed    


    February 2019
  56. ARAI T, Kojima S, Yamada Y, Sugawara S, et al
    Micro-ribonucleic acid expression signature of metastatic castration-resistant prostate cancer: Regulation of NCAPH by antitumor miR-199a/b-3p.
    Int J Urol. 2019 Feb 28. doi: 10.1111/iju.13911.
    PubMed     Abstract available


  57. KOGUCHI T, Haga N, Matsuoka K, Yabe M, et al
    Atherosclerosis as a predictor of transient exacerbation of overactive bladder symptoms after robot-assisted laparoscopic radical prostatectomy.
    Int J Urol. 2019;26:234-240.
    PubMed     Abstract available


    December 2018
  58. INOUE T
    Editorial Comment to Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer.
    Int J Urol. 2018 Dec 21. doi: 10.1111/iju.13887.
    PubMed    


  59. DING XF, Huang TB, Gao Y, Lu SM, et al
    Permanent (125) I prostate brachytherapy for castration-resistant prostate cancer.
    Int J Urol. 2018 Dec 4. doi: 10.1111/iju.13866.
    PubMed     Abstract available


    November 2018
  60. INOUE Y, Ushijima S, Shiraishi T, Fujihara A, et al
    Biochemical and magnetic resonance image response in targeted focal cryotherapy to ablate targeted biopsy-proven index lesion of prostate cancer.
    Int J Urol. 2018 Nov 28. doi: 10.1111/iju.13857.
    PubMed    


  61. SHIOTA M, Namitome R, Kobayashi T, Inokuchi J, et al
    Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer.
    Int J Urol. 2018 Nov 21. doi: 10.1111/iju.13870.
    PubMed    


  62. HAKOZAKI Y, Matsushima H, Murata T, Masuda T, et al
    Detection rate of clinically significant prostate cancer in magnetic resonance imaging and ultrasonography-fusion transperineal targeted biopsy for lesions with a prostate imaging reporting and data system version 2 score of 3-5.
    Int J Urol. 2018 Nov 21. doi: 10.1111/iju.13842.
    PubMed     Abstract available


  63. PATEL DN, Chapin BF, Freedland SJ
    Response to Editorial Comment to Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.
    Int J Urol. 2018 Nov 20. doi: 10.1111/iju.13861.
    PubMed    


  64. HAYASHI T, Fujita K, Matsushita M, Hayashi Y, et al
    Metformin inhibits prostate cancer growth induced by a high-fat diet in Pten-deficient model mice.
    Int J Urol. 2018 Nov 20. doi: 10.1111/iju.13847.
    PubMed    


    October 2018
  65. SAVELLI G, Zaniboni A, Stefanelli A
    Re: Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
    Int J Urol. 2018 Oct 24. doi: 10.1111/iju.13832.
    PubMed    


  66. POELAERT F, Schatteman P, Lumen N
    Editorial Comment to Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.
    Int J Urol. 2018 Oct 22. doi: 10.1111/iju.13837.
    PubMed    


    September 2018
  67. AFRIANSYAH A, Hamid ARA, Mochtar CA, Umbas R, et al
    Survival analysis and development of a prognostic nomogram for bone-metastatic prostate cancer patients: A single-center experience in Indonesia.
    Int J Urol. 2018 Sep 30. doi: 10.1111/iju.13813.
    PubMed     Abstract available


  68. YANO A, Kawakami S
    Re: Local treatment for metastatic prostate cancer: A systematic review.
    Int J Urol. 2018 Sep 30. doi: 10.1111/iju.13809.
    PubMed    


  69. PATEL DN, Jha S, Howard LE, Amling CL, et al
    Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.
    Int J Urol. 2018 Sep 25. doi: 10.1111/iju.13806.
    PubMed     Abstract available


  70. SCHIAVINA R, Chessa F, Borghesi M, Gaudiano C, et al
    State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer.
    Int J Urol. 2018 Sep 20. doi: 10.1111/iju.13797.
    PubMed     Abstract available


  71. CHOI SY, Ryu J, You D, Hong JH, et al
    Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean Cancer Study of the Prostate risk classification.
    Int J Urol. 2018 Sep 20. doi: 10.1111/iju.13800.
    PubMed     Abstract available


    August 2018
  72. FUJITA K, Nonomura N
    Urinary biomarkers of prostate cancer.
    Int J Urol. 2018 Aug 21. doi: 10.1111/iju.13734.
    PubMed     Abstract available


  73. REINSTATLER L, Carmichael D, Austin AM, Goodney PP, et al
    Regional variation in the intensity of prostate cancer care: A study of a large Medicare sample.
    Int J Urol. 2018 Aug 13. doi: 10.1111/iju.13775.
    PubMed    


    July 2018
  74. KANAO K, Kajikawa K, Kobayashi I, Morinaga S, et al
    Impact of a novel biopsy instrument with a 25-mm side-notch needle on the detection of prostate cancer in transrectal biopsy.
    Int J Urol. 2018 Jul 18. doi: 10.1111/iju.13722.
    PubMed     Abstract available


    June 2018
  75. SAKAMOTO S
    Editorial Comment to Epidemiology of prostate cancer in Asian countries.
    Int J Urol. 2018;25:531-532.
    PubMed    


    May 2018
  76. YANO A, Arai Y, Kitayama S, Otsuka Y, et al
    Effect of zoledronic acid dosing every 3 months in patients with prostate cancer with skeletal metastases: A multicenter prospective exploratory study with matched historical controls.
    Int J Urol. 2018 May 14. doi: 10.1111/iju.13703.
    PubMed    


  77. CHEN PY, Chiang PH, Liu YY, Chuang YC, et al
    Primary whole-gland ablation for localized prostate cancer with high-intensity focused ultrasound: The important predictors of biochemical recurrence.
    Int J Urol. 2018 May 13. doi: 10.1111/iju.13581.
    PubMed     Abstract available


  78. KIMURA T, Egawa S
    Epidemiology of prostate cancer in Asian countries.
    Int J Urol. 2018 May 8. doi: 10.1111/iju.13593.
    PubMed     Abstract available


  79. SAKAMOTO S
    Editorial Comment to Local treatment for metastatic prostate cancer: A systematic review.
    Int J Urol. 2018;25:403-404.
    PubMed    


    April 2018
  80. MITSUI Y
    Editorial Comment to Role of bone scan index in the prognosis and effects of therapy on prostate cancer with bone metastasis: Study design and rationale for the multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Sca
    Int J Urol. 2018 Apr 16. doi: 10.1111/iju.13582.
    PubMed    


  81. MEARINI L
    Editorial Comment to Evaluating the predictive accuracy and the clinical benefit of a nomogram aimed to predict survival in node-positive prostate cancer patients: External validation on a multi-institutional database.
    Int J Urol. 2018 Apr 12. doi: 10.1111/iju.13575.
    PubMed    


  82. KITAGAWA Y
    Editorial Comment to Prostate-specific antigen screening impacts on biochemical recurrence in patients with clinically localized prostate cancer.
    Int J Urol. 2018 Apr 12. doi: 10.1111/iju.13578.
    PubMed    


  83. IZUMI K
    Editorial Comment to Influence of prior oral ethinylestradiol use on the efficacy of enzalutamide for the treatment of castration-resistant prostate cancer in men.
    Int J Urol. 2018 Apr 12. doi: 10.1111/iju.13572.
    PubMed    


  84. TAKAMOTO A, Tanimoto R, Bekku K, Araki M, et al
    Oncological impact of neoadjuvant hormonal therapy on permanent iodine-125 seed brachytherapy in patients with low- and intermediate-risk prostate cancer.
    Int J Urol. 2018 Apr 12. doi: 10.1111/iju.13555.
    PubMed     Abstract available


  85. NAKAJIMA K, Kaneko G, Takahashi S, Matsuyama H, et al
    Role of bone scan index in the prognosis and effects of therapy on prostate cancer with bone metastasis: Study design and rationale for the multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index (PROSTAT-BSI)
    Int J Urol. 2018 Apr 6. doi: 10.1111/iju.13556.
    PubMed     Abstract available


  86. HASHIMOTO T, Ohori M, Shimodaira K, Kaburaki N, et al
    Prostate-specific antigen screening impacts on biochemical recurrence in patients with clinically localized prostate cancer.
    Int J Urol. 2018 Apr 6. doi: 10.1111/iju.13563.
    PubMed     Abstract available


  87. BIANCHI L, Schiavina R, Borghesi M, Bianchi FM, et al
    Evaluating the predictive accuracy and the clinical benefit of a nomogram aimed to predict survival in node-positive prostate cancer patients: External validation on a multi-institutional database.
    Int J Urol. 2018 Apr 6. doi: 10.1111/iju.13565.
    PubMed     Abstract available


    March 2018
  88. OKIHARA K
    Editorial Comment to Impact of age on quality of life in patients with localized prostate cancer treated with high-dose rate brachytherapy combined with external beam radiotherapy.
    Int J Urol. 2018 Mar 25. doi: 10.1111/iju.13570.
    PubMed    


  89. TILKI D, Pompe RS, Bandini M, Marchioni M, et al
    Local treatment for metastatic prostate cancer: A systematic review.
    Int J Urol. 2018 Mar 23. doi: 10.1111/iju.13535.
    PubMed     Abstract available


  90. HAKARIYA T, Shida Y, Tsurusaki T, Watanabe J, et al
    Influence of prior oral ethinylestradiol use on the efficacy of enzalutamide for the treatment of castration-resistant prostate cancer in men.
    Int J Urol. 2018 Mar 8. doi: 10.1111/iju.13542.
    PubMed     Abstract available


  91. ALBERTS AR, Roobol MJ
    Editorial Comment to Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.
    Int J Urol. 2018;25:277.
    PubMed    


    February 2018
  92. KIKKAWA K, Iba A, Kohjimoto Y, Noda Y, et al
    Impact of age on quality of life in patients with localized prostate cancer treated with high-dose rate brachytherapy combined with external beam radiotherapy.
    Int J Urol. 2018 Feb 4. doi: 10.1111/iju.13530.
    PubMed     Abstract available


  93. AKAMATSU S, Inoue T, Ogawa O, Gleave ME, et al
    Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
    Int J Urol. 2018 Feb 3. doi: 10.1111/iju.13526.
    PubMed     Abstract available


    January 2018
  94. BEGEMANN D, Anastos H, Kyprianou N
    Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
    Int J Urol. 2018 Jan 17. doi: 10.1111/iju.13505.
    PubMed     Abstract available


  95. SAKAMOTO S
    Editorial Comment to Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
    Int J Urol. 2018 Jan 17. doi: 10.1111/iju.13510.
    PubMed    


  96. TAKEI A, Sakamoto S, Wakai K, Tamura T, et al
    Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy.
    Int J Urol. 2018 Jan 11. doi: 10.1111/iju.13521.
    PubMed     Abstract available


  97. MURATA Y, Tatsugami K, Yoshikawa M, Hamaguchi M, et al
    Predictive factors of biochemical recurrence after radical prostatectomy for high-risk prostate cancer.
    Int J Urol. 2018 Jan 8. doi: 10.1111/iju.13514.
    PubMed     Abstract available


    December 2017
  98. KOMURA K, Sweeney CJ, Inamoto T, Ibuki N, et al
    Current treatment strategies for advanced prostate cancer.
    Int J Urol. 2017 Dec 20. doi: 10.1111/iju.13512.
    PubMed     Abstract available


  99. NEUPANE S, Steyerberg E, Raitanen J, Talala K, et al
    Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.
    Int J Urol. 2017 Dec 10. doi: 10.1111/iju.13508.
    PubMed     Abstract available


    November 2017
  100. NAKANO M, Araki H, Ohtakara K, Tanaka H, et al
    Significance of total colonoscopy screening before definitive radiotherapy for prostate cancer on the detection of anorectocolonic disease requiring intervention in advance.
    Int J Urol. 2017 Nov 23. doi: 10.1111/iju.13494.
    PubMed    


    October 2017
  101. YANO A, Kagawa M, Takeshita H, Okada Y, et al
    Improved survival of men with metastatic prostate cancer treated with androgen deprivation therapy plus radiotherapy to the prostate.
    Int J Urol. 2017 Oct 23. doi: 10.1111/iju.13479.
    PubMed    


  102. MITSUZUKA K, Arai Y
    Metabolic changes in patients with prostate cancer during androgen deprivation therapy.
    Int J Urol. 2017 Oct 20. doi: 10.1111/iju.13473.
    PubMed     Abstract available


    September 2017
  103. SAIKA T, Miura N, Fukumoto T, Yanagihara Y, et al
    Role of robot-assisted radical prostatectomy in locally advanced prostate cancer.
    Int J Urol. 2017 Sep 13. doi: 10.1111/iju.13441.
    PubMed     Abstract available


  104. PEREIRA-AZEVEDO N, Braga I, Verbeek JF, Osorio L, et al
    Prospective evaluation on the effect of interobserver variability of digital rectal examination on the performance of the Rotterdam Prostate Cancer Risk Calculator.
    Int J Urol. 2017 Sep 13. doi: 10.1111/iju.13442.
    PubMed     Abstract available


  105. YANO A, Kagawa M, Takeshita H, Okada Y, et al
    Baseline low serum dehydroepiandrosterone sulfate can predict poor responsiveness to hormone therapy in patients with hormone-naive prostate cancer with skeletal metastases.
    Int J Urol. 2017 Sep 11. doi: 10.1111/iju.13445.
    PubMed    


    August 2017
  106. SAKAMOTO S
    Editorial Comment to Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition).
    Int J Urol. 2017 Aug 20. doi: 10.1111/iju.13436.
    PubMed    


  107. SAKAMOTO S
    Editorial Comment to Bone scan index: A new biomarker of bone metastasis in patients with prostate cancer.
    Int J Urol. 2017 Aug 6. doi: 10.1111/iju.13433.
    PubMed    


    July 2017
  108. DINH KT, Yang DD, Nead KT, Reznor G, et al
    Association between androgen deprivation therapy and anxiety among 78 000 patients with localized prostate cancer.
    Int J Urol. 2017 Jul 22. doi: 10.1111/iju.13409.
    PubMed     Abstract available


  109. KAKEHI Y, Sugimoto M, Taoka R
    Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition).
    Int J Urol. 2017 Jul 1. doi: 10.1111/iju.13380.
    PubMed     Abstract available


    June 2017
  110. NOGUCHI M, Koga N, Igawa T, Itoh K, et al
    Clinical development of immunotherapy for prostate cancer.
    Int J Urol. 2017 Jun 21. doi: 10.1111/iju.13397.
    PubMed     Abstract available


  111. MCGINLEY KF, Sun X, Howard LE, Aronson WJ, et al
    Characterization of a "low-risk" cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database.
    Int J Urol. 2017 Jun 6. doi: 10.1111/iju.13387.
    PubMed     Abstract available


  112. MIZOKAMI A, Kadono Y, Kitagawa Y, Izumi K, et al
    Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.
    Int J Urol. 2017 Jun 3. doi: 10.1111/iju.13372.
    PubMed     Abstract available


    May 2017
  113. ENATSU N
    Editorial Comment to Assessment of sexual function in Japanese men with prostate cancer undergoing permanent brachytherapy without androgen deprivation therapy: Analysis from the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Impl
    Int J Urol. 2017 May 31. doi: 10.1111/iju.13383.
    PubMed    


  114. NAKAJIMA K, Edenbrandt L, Mizokami A
    Bone scan index: A new biomarker of bone metastasis in patients with prostate cancer.
    Int J Urol. 2017 May 26. doi: 10.1111/iju.13386.
    PubMed     Abstract available


  115. MITSUZUKA K
    Editorial comment to Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naive castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.
    Int J Urol. 2017 May 21. doi: 10.1111/iju.13379.
    PubMed    


  116. YUASA T
    Editorial Comment to Identification of risk factors predicting febrile neutropenia in patients with metastatic germ cell tumors receiving cisplatin-based combination chemotherapy.
    Int J Urol. 2017 May 6. doi: 10.1111/iju.13365.
    PubMed    


    April 2017
  117. TERADA N, Maughan BL, Akamatsu S, Kobayashi T, et al
    Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naive castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.
    Int J Urol. 2017 Apr 28. doi: 10.1111/iju.13346.
    PubMed     Abstract available


  118. OKIHARA K, Yorozu A, Saito S, Tanaka N, et al
    Assessment of sexual function in Japanese men with prostate cancer undergoing permanent brachytherapy without androgen deprivation therapy: Analysis from the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation database.
    Int J Urol. 2017 Apr 28. doi: 10.1111/iju.13358.
    PubMed     Abstract available


  119. NISHIKAWA M, Miyake H, Fujisawa M
    Identification of risk factors predicting febrile neutropenia in patients with metastatic germ cell tumors receiving cisplatin-based combination chemotherapy.
    Int J Urol. 2017 Apr 18. doi: 10.1111/iju.13352.
    PubMed     Abstract available


    March 2017
  120. NARAYAN VM, Konety BR, Warlick C
    Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice.
    Int J Urol. 2017 Mar 27. doi: 10.1111/iju.13326.
    PubMed     Abstract available


    September 2016
  121. KAMADA S
    Editorial Comment to Behavior of chemiluminescent assays to measure serum testosterone during androgen deprivation therapy.
    Int J Urol. 2016 Sep 7. doi: 10.1111/iju.13195.
    PubMed    


    August 2016
  122. MOROTE J, Comas I, Planas J, Celma A, et al
    Behavior of chemiluminescent assays to measure serum testosterone during androgen deprivation therapy.
    Int J Urol. 2016 Aug 3. doi: 10.1111/iju.13180.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: